A BILL 
To direct the Secretary of Veterans Affairs to carry out 
a series of clinical trials on the effects of cannabis on 
certain health outcomes of veterans with chronic pain 
and post-traumatic stress disorder, and for other pur-
poses. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘VA Medicinal Cannabis 
4
Research Act of 2021’’. 
5
02:02 Jun 19, 2021
H2916
2 
•HR 2916 IH
SEC. 2. DEPARTMENT OF VETERANS AFFAIRS CLINICAL 
1
TRIALS ON THE EFFECTS OF CANNABIS ON 
2
CERTAIN HEALTH OUTCOMES OF VETERANS 
3
WITH CHRONIC PAIN AND POST-TRAUMATIC 
4
STRESS DISORDER. 
5
(a) CLINICAL TRIALS REQUIRED.— 
6
(1) IN GENERAL.—The Secretary of Veterans 
7
Affairs shall carry out a series of clinical trials on 
8
the effects of medical-grade cannabis on the health 
9
outcomes of covered veterans diagnosed with chronic 
10
pain and covered veterans diagnosed with post-trau-
11
matic stress disorder. 
12
(2) REQUIRED ELEMENTS.—The clinical trials 
13
required by paragraph (1) shall include— 
14
(A) with respect to covered veterans diag-
15
nosed with chronic pain, an evaluation of the 
16
effects of the use of cannabis on— 
17
(i) osteopathic pain (including pain in-
18
tensity and pain-related outcomes); 
19
(ii) the reduction or increase in opioid 
20
use or dosage; 
21
(iii) the reduction or increase in 
22
benzodiazepine use or dosage; 
23
(iv) the reduction or increase in alco-
24
hol use; 
25
(v) inflammation; 
26
02:02 Jun 19, 2021
H2916
3 
•HR 2916 IH
(vi) sleep quality; 
1
(vii) agitation; and 
2
(viii) quality of life; 
3
(B) with respect to covered veterans diag-
4
nosed with post-traumatic stress disorder, an 
5
evaluation of the effects of the use of cannabis 
6
on— 
7
(i) the symptoms of post-traumatic 
8
stress disorder (PTSD) as established by 
9
or derived from the clinician administered 
10
PTSD scale, the PTSD checklist, the 
11
PTSD symptom scale, the post-traumatic 
12
diagnostic scale, and other applicable 
13
methods of evaluating symptoms of post- 
14
traumatic stress disorder; 
15
(ii) the reduction or increase in 
16
benzodiazepine use or dosage; 
17
(iii) the reduction or increase in alco-
18
hol use; 
19
(iv) mood; 
20
(v) anxiety; 
21
(vi) social functioning; 
22
(vii) agitation; 
23
(viii) suicidal ideation; and 
24
02:02 Jun 19, 2021
H2916
4 
•HR 2916 IH
(ix) sleep quality, including frequency 
1
of nightmares and night terrors. 
2
(3) OPTIONAL ELEMENTS.—The clinical trials 
3
required by paragraph (1) may include an evaluation 
4
of the effects of the use of cannabis to treat chronic 
5
pain and post-traumatic stress disorder on— 
6
(A) pulmonary function; 
7
(B) cardiovascular events; 
8
(C) head, neck, and oral cancer; 
9
(D) testicular cancer; 
10
(E) ovarian cancer; 
11
(F) transitional cell cancer; 
12
(G) intestinal inflammation; 
13
(H) motor vehicle accidents; 
14
(I) mania; 
15
(J) psychosis; 
16
(K) cognitive effects; 
17
(L) cannabinoid hyperemesis syndrome; 
18
(M) neuropathy; or 
19
(N) spasticity. 
20
(b) LONG-TERM OBSERVATIONAL STUDY.—The Sec-
21
retary may carry out a long-term observational study of 
22
the participants in the clinical trials required by sub-
23
section (a). 
24
(c) TYPE OF CANNABIS.— 
25
02:02 Jun 19, 2021
H2916
5 
•HR 2916 IH
(1) IN GENERAL.—In carrying out the clinical 
1
trials required by subsection (a), the Secretary shall 
2
study varying forms of cannabis, including whole 
3
plant raw material and extracts. 
4
(2) PLANT CULTIVARS.—Of the varying forms 
5
of cannabis required under paragraph (1), the Sec-
6
retary shall study not fewer than seven unique plant 
7
cultivars with ratios of tetrahydrocannabinol to 
8
cannabidiol in each of the following categories: 
9
(A) Less than 1:5. 
10
(B) Between 1:2 and 1:5. 
11
(C) Approximately 1:2. 
12
(D) Approximately 1:1. 
13
(E) Approximately 2:1. 
14
(F) Between 2:1 and 5:1. 
15
(G) More than 5:1. 
16
(d) 
USE
OF
CONTROL
AND
EXPERIMENTAL 
17
GROUPS.—The clinical trials required by subsection (a) 
18
shall include both a control group and an experimental 
19
group that shall— 
20
(1) be of similar size and structure; and 
21
(2) represent the demographics of the veteran 
22
population, as determined by the most recent data 
23
from the American Community Survey of the Bu-
24
02:02 Jun 19, 2021
H2916
6 
•HR 2916 IH
reau of the Census that is available prior to the 
1
commencement of the clinical trials. 
2
(e) DATA PRESERVATION.—The clinical trials re-
3
quired by subsection (a) shall include a mechanism to en-
4
sure the preservation of all data, including all data sets, 
5
collected or used for purposes of such trials in a manner 
6
that will facilitate further research. 
7
(f) IMPLEMENTATION.—Not later than 180 days 
8
after the date of the enactment of this Act, the Secretary 
9
shall— 
10
(1) develop a plan to implement this section 
11
and submit such plan to the Committee on Veterans’ 
12
Affairs of the Senate and the Committee on Vet-
13
erans’ Affairs of the House of Representatives; and 
14
(2) issue any requests for proposals the Sec-
15
retary determines appropriate for such implementa-
16
tion. 
17
(g) EFFECT ON OTHER BENEFITS.—The eligibility 
18
or entitlement of a covered veteran to any other benefit 
19
under the laws administered by the Secretary or any other 
20
provision of law shall not be affected by the participation 
21
of the covered veteran in a clinical trial under subsection 
22
(a) or a study under subsection (b). 
23
(h) PERIODIC REPORTS.—During the five-year pe-
24
riod beginning on the date of the enactment of this Act, 
25
02:02 Jun 19, 2021
H2916
7 
•HR 2916 IH
the Secretary shall submit periodically, but not less fre-
1
quently than annually, to the Committee on Veterans’ Af-
2
fairs of the Senate and the Committee on Veterans’ Af-
3
fairs of the House of Representatives reports on the imple-
4
mentation of this section. 
5
(i) COVERED VETERAN DEFINED.—In this section, 
6
the term ‘‘covered veteran’’ means a veteran who is en-
7
rolled in the patient enrollment system of the Department 
8
of Veterans Affairs established and operated under section 
9
1705(a) of title 38, United States Code. 
10
Æ 
02:02 Jun 19, 2021
H2916
